Could a new score spare men from unnecessary prostate biopsies?

NCT ID NCT07753356

Not yet recruiting Diagnosis Sponsor: Marcelo Ruben Oliva Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study is testing whether a new scoring system, called the Fusion CEMEP score, can safely guide prostate biopsy decisions. The goal is to see if men with suspected prostate cancer can skip the extra systematic biopsies and only have targeted biopsies based on MRI findings. The study will compare the detection rate of significant prostate cancer using this score-guided approach against the standard full biopsy scheme. If the score works, it could reduce unnecessary procedures and overtreatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fusion CEMEP score-guided biopsy strategy
What this could lead to: If successful, this could help many men avoid extra prostate biopsies, reducing discomfort and overtreatment while still catching significant cancers.
What could go wrong: The score is still being validated, and it may not be accurate enough to safely skip biopsies in all cases. Missing a significant cancer is a serious risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATIC NEOPLASMS/DIAGNOSIS

Contacts and locations

Locations

Clinica Cemep

Rio Grande, Tierra del Fuego Province, 9420, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.